Daily application of roflumilast cream for 52 weeks improves the signs and symptoms of AD in patients with various comorbid atopic conditions.

Organon & Co. OGN recently announced findings from a pooled sub-analysis of its Phase 3 ADORING 1 and ADORING 2 pivotal trials assessing VTAMA (tapinarof) cream, 1%, in pediatric patients with ...

Among patients aged 2 to 17 years with moderate to severe atopic dermatitis, tapinarof cream 1% significantly improved sleep, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. AD affected more than 35% body surface area of study ...

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved ...

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

After years of perioral dermatitis flare-ups, beauty journalist Emma Stoddart simplified her routine and leaned into ...

Credit: Getty Images. No new safety signals were observed in this patient population. Positive topline results were announced from a phase 3 trial evaluating the efficacy and safety of ruxolitinib ...

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...

Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this ...

WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in ...